This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Trenbolone Enanthate
Trenbolone delivered as a long-acting enanthate ester (~5-7 day half-life) so users can inject 1-2× weekly instead of every other day.
Aliases (4)
Overview
What is Trenbolone Enanthate?
Trenbolone enanthate is a long-acting injectable ester (~7-10 day half-life) of the potent anabolic-androgenic steroid trenbolone, formulated for less frequent injections than the shorter acetate ester. It is a non-FDA-approved compound used in bodybuilding.
Key Benefits
Same anabolic and side-effect profile as trenbolone base — large lean muscle gains, fat loss, strength increase — with the convenience of weekly or biweekly injections instead of daily/EOD acetate dosing.
Mechanism of Action
After IM injection, the enanthate ester is hydrolyzed slowly to release trenbolone, which binds the androgen receptor with very high affinity. Trenbolone does not aromatize, has progestin agonism, antagonizes glucocorticoid receptors (anti-catabolic), and produces strong nutrient-partitioning effects toward muscle accretion.
Pharmacokinetics
▸ Vial inspection & sterile draw AAS oil
AAS oil arrives pre-suspended in carrier oil — no BAC water needed. Inspect for clarity, color, and crashed compound (cold storage can crystallize). Warm vial in palm or under hot tap before draw.
- 1 Wipe vial stopper with isopropyl alcohol.
- 2 Warm vial 30-60s in palm if oil is cold/cloudy.
- 3 Draw with 18g needle into 22-25g pin barrel for IM, or 27-29g for sub-Q.
- 4 Tap out air bubbles, expel a small drop, then inject at chosen site.
▸ Cycle structure & PCT AAS
Ramp dose over week 1, hold steady through cycle weeks. Track baseline labs (TT/FT/E2/SHBG/HCT/lipids/LFTs) at week 0; recheck at week 4 and end-of-cycle.
On the last dose, the ester clears over its half-life window (enanthate = est. 7 days). PCT begins after the active compound has cleared.
Standard PCT is enclomiphene 12.5-25 mg/day or clomid 50/50/25/25 over 4 weeks (or nolvadex 20/20/10/10). HCG bridge optional during cycle to preserve testicular volume + faster restart. Bloodwork at PCT week 4 + 8 to confirm HPG axis recovery (LH, FSH, TT back to baseline).
Research Indications
Glucocorticoid receptor (GR) agonist
drives anxiety, sleep destruction, cardiovascular damage, connective-tissue catabolism (the "tren-class" subjective profile, distinct fro…
Progestogenic activity
binds progesterone receptor, can drive prolactin elevation and gynecomastia. AIs do not address this; cabergoline often added.
Non-aromatizing
does not convert to estradiol, removing estrogen's HDL/vascular protection → lipid disaster.
5α-reductase resistant
does not convert to DHT but is itself extraordinarily androgenic.
HPG suppression: among the most severe of any AAS
LH/FSH crash within days of any tren ester; recovery slow and uncertain.
Peptide Interactions
stacking compounds the cardiovascular and HPG damage non-linearly.
stacking the parent and the methylated oral version is a sport-history move with severe combined hepatotoxic + tren-class burden.
additive cardiovascular load; tren already raises HR/BP significantly. This is directly relevant for the canonical stack modafinil onboarding — running modaf…
interacts unpredictably with the AAS-mood axis.
class-leading hepatotoxicity layered onto tren-class damage; no harm-reduction win.
Quality Indicators
White, fluffy cake (peptides)
Lyophilized peptide should appear as a white, fluffy "cake" filling most of the vial bottom. Indicates proper freeze-drying.
Clear solution after reconstitution
After mixing with bacteriostatic water, the solution should be crystal clear with no particles or cloudiness.
Slight clumping acceptable
Small clumps that fully dissolve with gentle swirling are normal — shipping can cause minor compaction.
Collapsed or melted powder
Powder that looks collapsed, melted, or stuck to vial sides may have been heat-damaged in transit.
Cloudy or particulate solution
Persistent cloudiness or visible particles after gentle mixing indicate degraded or contaminated material.
What to Expect
- Week 1-2Frontload phase. Strength gains start; appetite up.
- Week 3-4Visible muscle fullness and recovery acceleration.
- Week 5-8Peak performance window. Monitor blood pressure + libido.
- Post-cyclePCT week 1-4. Bloodwork at week 6 post-cycle.
Side Effects & Safety
- Common (>10% users): Insomnia (universal), night sweats (universal), mood lability, irritability, anxiety, elevated resting HR, elevated BP, sexual dysfunction (mid-cycle ED), decreased cardio capacity, severe HPG suppression (universal). Continuous exposure on enanthate means no pulsatile relief from these.
- Less common (1-10%): Gynecomastia (progestogenic — AI does not help, cabergoline may), aggression incidents, panic-attack-like episodes, gross sleep architecture disruption, kidney function decline, hair-loss acceleration in genetically predisposed users, severe acne, depression (especially during PCT crash).
- Rare-serious (<1% but worth knowing):
- Acute kidney injury, FSGS-like pathology, rhabdomyolysis-associated AKI.
- Cardiac event (MI, arrhythmia, cardiomyopathy) — HDL crash + hypertension + erythrocytosis + GR activation stack acutely.
- Sleep apnea or sleep apnea worsening — AAS broadly worsen sleep apnea via airway tissue changes and weight gain; tren's sleep architecture damage compounds.
- Psychotic episode, manic episode, suicidal ideation — vulnerable users.
- Persistent post-cycle hypogonadism — failure to recover endogenous T after a single cycle is documented for tren-class. Some users require lifelong TRT after one Tren cycle.
- Tren cough — acute pulmonary reaction during injection (bronchospasm, metallic taste, cough fit lasting minutes; usually self-limited but distressing). Less common with enanthate than acetate.
- Specific watch periods:
- Lifetime: brain development incomplete until ~25; high-AR + high-GR exposure during this window has unstudied long-term consequences for HPA-axis setpoint, mood circuitry, AR sensitization. Tren E's continuous exposure profile makes this worse than pulsatile acetate, not better.
- First 4 weeks (steady-state buildup): psychiatric side effects ramp as blood levels reach plateau; sleep destruction often peaks here.
- Mid-cycle through PCT: sexual dysfunction, lipid damage, kidney/cardiac surveillance.
- Week 12-16 (fade-out): long ester means side effects persist 3-4 weeks after last injection — users sometimes mistake fade-out symptoms for PCT-crash.
- 6-12 months post-cycle: ASIH may persist; some users never recover.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.